Crescent Biopharma (CBIO) Receivables (2015 - 2025)
Crescent Biopharma (CBIO) reported Receivables of $18.0 million for Q4 2025, up 13079.09% year-over-year from N/an in Q4 2024, and up 13079.09% quarter-over-quarter from $136580.0 in Q4 2024.
Crescent Biopharma (CBIO) Receivables (2015 - 2025) Analysis & Trends
Crescent Biopharma (CBIO) has 3 years of Receivables data on file, last reported at $18.0 million in Q4 2025.
- Receivables for Q4 2025 came in at $18.0 million, up 13079.09% year-over-year; the trailing twelve-month figure through Dec 2025 was $18.0 million (up 13079.09% YoY), and the FY2025 annual result was $18.0 million, up 13079.09% from the prior year.
- Receivables grew to $18.0 million in Q4 2025 per CBIO's latest filing, from $136580.0 in the prior quarter.
- Over five years, Receivables peaked at $18.0 million in Q4 2025 and troughed at $136580.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Crescent Biopharma | 486.92 Mn | 297.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.00 Mn |
| Dec 31, 2024 | 136,580.00 |
| Jun 30, 2015 | 20.00 Mn |